Medpace Holdings Inc (MEDP)vsWaters Corporation (WAT)
MEDP
Medpace Holdings Inc
$466.80
+1.32%
HEALTHCARE · Cap: $13.08B
WAT
Waters Corporation
$302.32
+0.13%
HEALTHCARE · Cap: $29.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 25% more annual revenue ($3.17B vs $2.53B). WAT leads profitability with a 20.3% profit margin vs 17.8%. WAT appears more attractively valued with a PEG of 1.25. MEDP earns a higher WallStSmart Score of 70/100 (B-).
MEDP
Strong Buy70
out of 100
Grade: B-
WAT
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+40.8%
Fair Value
$716.04
Current Price
$466.80
$249.24 discount
Margin of Safety
-349.9%
Fair Value
$73.17
Current Price
$302.32
$229.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 70 in profit
Revenue surging 32.0% year-over-year
Strong operational efficiency at 21.6%
Earnings expanding 26.9% YoY
Strong operational efficiency at 33.8%
Safe zone — low bankruptcy risk
Every $100 of equity generates 29 in profit
Keeps 20 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.9x book value
Moderate valuation
Earnings declined 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : MEDP
The strongest argument for MEDP centers on Return on Equity, Revenue Growth, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 21.6%. Revenue growth of 32.0% demonstrates continued momentum.
Bull Case : WAT
The strongest argument for WAT centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 20.3% and operating margin at 33.8%. PEG of 1.25 suggests the stock is reasonably priced for its growth.
Bear Case : MEDP
The primary concerns for MEDP are PEG Ratio, P/E Ratio, Price/Book.
Bear Case : WAT
The primary concerns for WAT are P/E Ratio, EPS Growth.
Key Dynamics to Monitor
MEDP profiles as a growth stock while WAT is a mature play — different risk/reward profiles.
MEDP carries more volatility with a beta of 1.46 — expect wider price swings.
MEDP is growing revenue faster at 32.0% — sustainability is the question.
MEDP generates stronger free cash flow (188M), providing more financial flexibility.
Bottom Line
MEDP scores higher overall (70/100 vs 60/100), backed by strong 17.8% margins and 32.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medpace Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?